Compare Abeona Therapeutics Inc (ABEO) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs SoundHound AI Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while SoundHound AI Inc trades at $6.74 (market cap $2.88B). The key difference: SoundHound AI Inc is far larger — about 7.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SOUN | |
|---|---|---|
Market Cap | $373.32M | $2.88B |
Sector | Health | Technology |
52-Week High | $7.23 | $21.40 |
52-Week Low | $4.17 | $5.90 |
Enterprise Value | $228.22M | $2.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SoundHound AI (SOUN) trades at $6.96, up 6.26% on the day, with a bearish technical signal despite recent positive earnings beats. The company shows strong revenue growth in auto and IoT AI segments, up 88% year-over-year in Q1 2026, but faces profitability challenges with a net income margin of -91.84% and negative cash flow from operations. Analyst sentiment remains bullish with a $13.00 consensus price target, though the stock is down 37% year-to-date amid concerns over the LivePerson acquisition and high valuation multiples.
The outlook hinges on SOUN's ability to achieve profitability through scaling and cost synergies from acquisitions. Investment opportunities include market expansion in telecom and energy sectors, while risks involve persistent cash burn, competitive pressures, and execution risks in integrating LivePerson. The stock's high short interest could lead to volatility, but analyst optimism suggests potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
